Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Administration of Study Drug in Fed State – V 2.0

Posted on By

BA-BE Studies: SOP for Administration of Study Drug in Fed State – V 2.0

Standard Operating Procedure for Administration of Study Drug in Fed State in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/059/2025
Supersedes SOP/BA-BE/059/2022
Page No. Page 1 of 11
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized procedure for administering the investigational product (IP) under fed conditions to healthy volunteers in Bioavailability/Bioequivalence (BA/BE) studies as per protocol, regulatory, and GCP requirements.

2. Scope

This SOP applies to all fed studies conducted in the BA/BE clinical facility where the administration of the study drug is scheduled after a high-fat, high-calorie meal, as defined by regulatory guidelines and study protocols.

3. Responsibilities

  • Clinical Research Coordinator: Ensures subject compliance with fed state protocol and schedules meal and dosing.
  • Ward Nurse: Supervises food intake and assists during dosing.
  • Principal Investigator/Sub-Investigator: Approves readiness for dosing and oversees drug administration.
See also  BA-BE Studies: SOP for Subject Enrolment and Randomization Process - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring that dosing under fed conditions is compliant with the study protocol and regulatory standards.

5. Procedure

5.1 Standard Meal Composition

  1. Prepare a standardized high-fat, high-calorie breakfast containing approximately:
    • ~800-1000 kcal
    • ~50% fat, ~30% carbohydrate, ~20% protein
  2. Examples: Eggs, buttered toast, fried potatoes, milkshake.
  3. Document actual meal served in Annexure-1: Standard Fed Meal Record.

5.2 Meal Timing and Supervision

  1. Subjects must consume the entire meal within 30 minutes under supervision.
  2. Record start and end time of the meal in Annexure-2: Meal Intake Monitoring Log.
  3. Ensure no food or drink is consumed post-meal other than water (as per protocol).

5.3 Study Drug Administration

  1. Dose the subject exactly 30 minutes after completion of the fed meal, unless otherwise specified in the protocol.
  2. Verify subject identity and treatment allocation before dosing.
  3. Document exact dosing time, formulation, and initials of personnel in Annexure-3: Fed-State Dosing Record.
See also  BA-BE Studies: SOP for Project Risk Identification and Mitigation - V 2.0

5.4 Post-Dose Monitoring

  1. Observe subjects for any immediate adverse events post-dosing.
  2. Maintain subject fasting for the post-dose duration as defined in protocol (e.g., 4 hours).
  3. Document any protocol deviations or issues encountered.

5.5 Criteria for Exclusion

  1. If a subject does not complete the meal or vomits before dosing, consult the PI for continuation decision.
  2. Document such events in deviation log and Annexure-4: Fed-State Dosing Exclusion Log.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • IP: Investigational Product
  • PI: Principal Investigator

7. Documents

  1. Standard Fed Meal Record – Annexure-1
  2. Meal Intake Monitoring Log – Annexure-2
  3. Fed-State Dosing Record – Annexure-3
  4. Fed-State Dosing Exclusion Log – Annexure-4

8. References

  • US FDA Guidance on Food-Effect Bioavailability and Fed Studies
  • ICH E6(R2) – Good Clinical Practice
  • Study Protocol

See also  BA-BE Studies: SOP for ECG Monitoring Before Dosing - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Standard Fed Meal Record

Subject ID Meal Items Calories Fat % Meal Supervisor
VOL-059 Omelette, toast, butter, milkshake 950 52% Sunita Reddy

Annexure-2: Meal Intake Monitoring Log

Subject ID Meal Start Time Meal End Time Compliance Remarks
VOL-059 07:00 07:25 Yes Full meal consumed

Annexure-3: Fed-State Dosing Record

Subject ID Dosing Time IP Code Dosed By Remarks
VOL-059 07:55 TEST-A Dr. Arvind Shah No issues

Annexure-4: Fed-State Dosing Exclusion Log

Subject ID Reason for Exclusion Action Taken Investigator Date
VOL-059X Incomplete meal Excluded from dosing Dr. Arvind Shah 17/04/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
14/01/2022 1.0 Initial Release Protocol implementation QA Head
17/04/2025 2.0 Fed-state specific annexures added Compliance with US FDA Fed Study Guidelines QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Conducting Concurrent Process Validation – V 2.0
Next Post: Tablets: SOP for Visual Inspection of Packed Tablets – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version